Abstract:Alzheimer's disease (AD) is the fifth leading cause of death among adults aged 65 and older, yet the onset and progression of the disease is poorly understood. What is known is that the presence of amyloid, particularly polymerized Aβ42, defines when people are on the AD continuum. Interestingly, as AD progresses, less Aβ42 is detectable in the plasma, a phenomenon thought to result from Aβ becoming more aggregated in the brain and less Aβ42 and Aβ40 being transported from the brain to the plasma via the CSF. We propose that extracellular vesicles (EVs) play a role in this transport. EVs are found in bodily fluids such as blood, urine, and cerebrospinal fluid and carry diverse "cargos" of bioactive molecules (e.g., proteins, nucleic acids, lipids, metabolites) that dynamically reflect changes in the cells from which they are secreted. While Aβ42 and Aβ40 have been reported to be present in EVs, it is not known whether this interaction is specific for these peptides and thus whether amyloid-carrying EVs play a role in AD and/or serve as brain-specific biomarkers of the AD process. To determine if there is a specific interaction between Aβ and EVs, we used isothermal titration calorimetry (ITC) and discovered that Aβ42 and Aβ40 bind to EVs in manner that is sequence specific, saturable, and endothermic. In addition, Aβ incubation with EVs overnight yielded larger amounts of bound Aβ peptide that was fibrillar in structure. These findings point to a specific amyloid–EV interaction, a potential role for EVs in the transport of amyloid from the brain to the blood, and a role for this amyloid pool in the AD process.

What problem does this paper attempt to address?

The paper primarily explores the specific binding between β-amyloid protein (Aβ) and extracellular vesicles (EVs) in Alzheimer's disease (AD). ### Research Background - Alzheimer's disease is the 5th leading cause of death among adults aged 65 and older, but the mechanisms of its onset and progression are still unclear. - The presence of β-amyloid protein (especially the aggregated form Aβ42) is considered a key biomarker for determining whether an individual is in the process of Alzheimer's disease. - During the progression of Alzheimer's disease, the level of Aβ42 in plasma decreases, which is believed to be due to increased aggregation of Aβ in the brain and reduced transport from the brain to the plasma. ### Research Objectives - To explore the potential role of extracellular vesicles (EVs) in the transport of Aβ from the brain to the blood. - To determine whether there is specific binding between Aβ and EVs and whether this binding has biological significance in the process of Alzheimer's disease. - To study the thermodynamic properties of the binding between Aβ and EVs to further understand the molecular mechanisms of their interaction. ### Research Methods - Using Isothermal Titration Calorimetry (ITC) and Single Molecule Array (SIMOA) technology to analyze the specific binding between Aβ peptides and EVs. - Applying Atomic Force Microscopy (AFM) to observe structural changes after the binding of Aβ and EVs. ### Main Findings - Researchers found that Aβ42 and Aβ40 can specifically bind to EVs, and this binding exhibits sequence specificity, saturation, and endothermic properties. - After overnight incubation, the amount of Aβ peptides bound to EVs significantly increased and formed fibrillar structures. - These results indicate the existence of specific interactions between Aβ and EVs, suggesting that EVs may be involved in the transport of Aβ from the brain to the blood, and that the pool of Aβ in this process may play a role in the progression of Alzheimer's disease. In summary, this study aims to explore the specific interaction between Aβ and EVs and its potential physiological significance, providing a new perspective for further revealing the pathogenesis of Alzheimer's disease.

Specific Binding of Alzheimer's Aβ Peptides to Extracellular Vesicles

Extracellular Vesicle-Associated Aβ Mediates Trans-Neuronal Bioenergetic and Ca2+-Handling Deficits in Alzheimer's Disease Models

Real-Time Analysis of Specific Binding between Apolipoprotein E Isoforms and Amyloid β-Peptide by Dual Polarization Interferometry

Atomistic Characterization of Binding Modes and Affinity of Peptide Inhibitors to Amyloid-Β Protein

Amyloid-β-interacting proteins in peripheral fluids of Alzheimer’s disease

Blood extracellular vesicles carrying synaptic function‐ and brain‐related proteins as potential biomarkers for Alzheimer's disease

Endoplasmic Reticulum and Trans-Golgi Network Generate Distinct Populations of Alzheimer Beta-Amyloid Peptides

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer's Disease Therapeutic Antibodies.

Brain Tissue-Derived Extracellular Vesicles in Alzheimer's Disease Display Altered Key Protein Levels Including Cell Type-Specific Markers

Potential Roles of Extracellular Vesicles as Diagnosis Biomarkers and Therapeutic Approaches for Cognitive Impairment in Alzheimer's Disease.

Extracellular Vesicles Isolated from Familial Alzheimer's Disease Neuronal Cultures Induce Aberrant Tau Phosphorylation in the Wild-Type Mouse Brain

A Toxicogenic Interaction between Intracellular Amyloid-β and Apolipoprotein-E

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies

Novel method for collecting hippocampal interstitial fluid extracellular vesicles (EVISF) reveals sex‐dependent changes in microglial EV proteome in response to Aβ pathology

Membrane Binding and Pore Formation by a Cytotoxic Fragment of Amyloid β Peptide.

Advances in targeted tracking and detection of soluble amyloid-β aggregates as a biomarker of Alzheimer's disease

Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies

Potential Roles of Extracellular Vesicles As Diagnosis Biomarkers and Therapeutic Approaches for Cognitive Impairment in Alzheimer’s Disease

Endosomal dysfunction impacts extracellular vesicle release: Central role in Aβ pathology

Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer's disease

Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane